Phase II, Non-randomized, Open-label Study to Assess the Immunogenicity and Clinical Efficacy of the Recombinant Zoster Vaccine for Recipients of an Allogeneic Hematopoietic Stem Cell Transplant
This is a phase II study that will examine the immunogenicity of the Shingrix vaccine in patients following an allogeneic stem cell transplant.
• Age ≥18 years
• ≥ 12 months and ≤ 36 months post-AlloSCT
• Donor sources: matched related, matched unrelated, cord blood
• Any malignant hematological disease including acute leukemia, myelodysplastic syndrome, non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, and myeloproliferative disorders.
• Any conditioning regimen
• Any planned immunosuppressive prophylactic regimen
• Patients with chronic graft-versus-host disease on stable immunosuppression
• Ability to understand and the willingness to sign a written informed consent.
• Negative pregnancy test in female patients of childbearing potential